Clinical Trial Detail

NCT ID NCT04111510
Title Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Yale University
Indications

triple-receptor negative breast cancer

Therapies

LN-145

Age Groups: adult senior

No variant requirements are available.